## Attention: Medicaid Fee-for-Service Providers Dispense Brand Drugs When Less Expensive Program

## Effective August 30, 2012,

**Uroxatral** will be **removed** from the Dispense Brand Drugs When Less Expensive Program

and

**Symbyax, Ziagen tablet and Catapres-TTS** will be **added** to the Dispense Brand Drugs When Less Expensive Program

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription;
- have a generic copayment;
- will be paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (neither the SMAC nor FUL will be applied)

## **IMPORTANT BILLING INFORMATION**

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense As Written/Product Selection Code of '1'; and **Pharmacies can submit any valid NCPDP field (408-D8) value.** 

## Current list of Brand name drugs included in this program\* (Date Revised 8/30/2012):

Adderall XR	Epivir
Arixtra	Kadian
Astelin	Lexapro
Carbatrol	Lovenox
Catapres-TTS	Nasacort AQ
Combivir	Symbyax
Concerta	Valtrex
Diastat	Ziagen tablet
Geodon	

<sup>\*</sup> List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs; again promoting the use of the most cost-effective product.